Vés al contingut (premeu Retorn)

O. Estupiñán et al. Mithramycin delivery systems to develop effective therapies in sarcomas. Journal of Nanobiotechnology

Sou a: Inici / Portlet Papers / O. Estupiñán et al. Mithramycin delivery systems to develop effective therapies in sarcomas. Journal of Nanobiotechnology

O. Estupiñán et al. Mithramycin delivery systems to develop effective therapies in sarcomas. Journal of Nanobiotechnology

O. Estupiñán, E. Niza, I. Bravo, V. Rey, J. Tornín, B. Gallego, P. Clemente-Casares, F. Moris, A. Ocaña, V. Blanco-Lorenzo, M.Rodríguez-Santamaría, A. Vallina-Álvarez, M.V. González, A. Rodríguez, D. Hermida-Merino, C. Alonso-Moreno, R. Rodríguez. Mithramycin delivery systems to develop effective therapies in sarcomas. Journal of Nanobiotechnology. 2021 Sep 6;19(1):267.

doi: 10.1186/s12951-021-01008-x

Abstract

Background - Sarcomas comprise a group of aggressive malignancies with very little treatment options beyond standard chemotherapy. Reposition of approved drugs represents an attractive approach to identify effective therapeutic compounds. One example is mithramycin (MTM), a natural antibiotic which has demonstrated a strong antitumour activity in several tumour types, including sarcomas. However, its widespread use in the clinic was limited by its poor toxicity profile.

Results - In order to improve the therapeutic index of MTM, we have loaded MTM into newly developed nanocarrier formulations. First, polylactide (PLA) polymeric nanoparticles (NPs) were generated by nanoprecipitation. Also, liposomes (LIP) were prepared by ethanol injection and evaporation solvent method. Finally, MTM-loaded hydrogels (HG) were obtained by passive loading using a urea derivative non-peptidic hydrogelator. MTM-loaded NPs and LIP display optimal hydrodynamic radii between 80 and 105 nm with a very low polydispersity index (PdI) and encapsulation efficiencies (EE) of 92 and 30%, respectively. All formulations show a high stability and different release rates ranging from a fast release in HG (100% after 30 min) to more sustained release from NPs (100% after 24 h) and LIP (40% after 48 h). In vitro assays confirmed that all assayed MTM formulations retain the cytotoxic, anti-invasive and anti-stemness potential of free MTM in models of myxoid liposarcoma, undifferentiated pleomorphic sarcoma and chondrosarcoma. In addition, whole genome transcriptomic analysis evidenced the ability of MTM, both free and encapsulated, to act as a multi-repressor of several tumour-promoting pathways at once. Importantly, the treatment of mice bearing sarcoma xenografts showed that encapsulated MTM exhibited enhanced therapeutic effects and was better tolerated than free MTM.

Conclusions - Overall, these novel formulations may represent an efficient and safer MTM-delivering alternative for sarcoma treatment.

 

Mithramycin delivery systems to develop effective therapies in sarcomas

arxivat sota: